Thompson Siegel & Walmsley LLC acquired a new stake in Myomo, Inc. (NYSEAMERICAN:MYO – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 200,000 shares of the company’s stock, valued at approximately $1,288,000.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of MYO. Barclays PLC bought a new position in Myomo in the third quarter valued at approximately $36,000. Jane Street Group LLC bought a new position in Myomo in the third quarter valued at approximately $65,000. XTX Topco Ltd bought a new position in Myomo in the third quarter valued at approximately $149,000. Thompson Davis & CO. Inc. bought a new position in Myomo in the fourth quarter valued at approximately $181,000. Finally, Calamos Advisors LLC bought a new position in Myomo in the fourth quarter valued at approximately $189,000. 44.99% of the stock is owned by institutional investors.
Myomo Trading Up 2.4 %
Shares of NYSEAMERICAN:MYO opened at $5.19 on Friday. Myomo, Inc. has a 12 month low of $2.51 and a 12 month high of $7.17. The firm has a market cap of $157.00 million, a P/E ratio of -22.57 and a beta of 1.68.
Insider Buying and Selling
Wall Street Analysts Forecast Growth
A number of equities analysts have recently weighed in on MYO shares. HC Wainwright lifted their price target on shares of Myomo from $7.50 to $9.50 and gave the stock a “buy” rating in a research report on Wednesday. Alliance Global Partners reissued a “buy” rating on shares of Myomo in a research report on Tuesday. Finally, Craig Hallum lifted their price target on shares of Myomo from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $9.25.
View Our Latest Research Report on MYO
Myomo Company Profile
Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.
Read More
- Five stocks we like better than Myomo
- Most active stocks: Dollar volume vs share volume
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Top Biotech Stocks: Exploring Innovation Opportunities
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- Stock Splits, Do They Really Impact Investors?
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Want to see what other hedge funds are holding MYO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myomo, Inc. (NYSEAMERICAN:MYO – Free Report).
Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.